TITLE

Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics

AUTHOR(S)
Bijkerk, C.J.; de Wit, N.J.; Muris, J.W.M.; Jones, R.H.; Knottnerus, J.A.; Hoes, A.W.
PUB. DATE
January 2003
SOURCE
American Journal of Gastroenterology;Jan2003, Vol. 98 Issue 1, p122
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
: ObjectivesAlthough there is growing interest in irritable bowel syndrome (IBS) research, there is as yet no consensus regarding the preferred outcome measure. We aimed to evaluate and to compare the validity and appropriateness of available IBS outcome measures.: MethodsIBS symptom and IBS health-related quality of life (HRQOL) scales were identified through a literature search. In a panel evaluation, six reviewers independently rated the scales according to predetermined psychometric and methodological validation criteria.: ResultsFive IBS symptom scales and five IBS HRQOL instruments were identified. Two of the symptom scales were rated as good. The Adequate Relief question scored best. This scale demonstrates responsiveness as well as face and construct validity, and its score was considered easy to interpret and appropriate for use. According to the reviewers, the IBS Severity Scoring System performed well with regard to psychometric capacities, but its practical utility was considered debatable. The properties of the other three symptom scales were suboptimal. The practical utility of the five IBS-specific HRQOL scales was considered poor. However, the reviewers agreed that, at present, the IBS Quality of Life measurement (Patrick et al.) is the best choice, because it has been the most extensively validated and shows appropriate psychometric quality.: ConclusionsThe Adequate Relief question is the measure of first choice when assessing global symptomatology as an outcome in IBS studies. For a more detailed IBS symptom assessment, the IBS Severity Scoring System is preferable. Finally, the IBS Quality of Life measurement scale can be used to establish changes in health-related quality of life.
ACCESSION #
8903817

 

Related Articles

  • FUNCTIONAL RELAXATION AS COMPLEMENTARY THERAPY IN IRRITABLE BOWEL SYNDROME. ROBERTSHAWE, PENNY // Journal of the Australian Traditional-Medicine Society;Jun2010, Vol. 16 Issue 2, p101 

    The article discusses research which was conducted to compare the efficacy of functional relaxation and enhanced medical care in treating the psychosomatic factors associated with irritable bowel syndrome (IBS). Researchers evaluated 80 IBS patients. They found that functional relaxation led to...

  • Burden of constipation-predominant irritable bowel syndrome (IBS-C) in France, Italy, and the United Kingdom. daCosta, Marco; DiBonaventura; Prior, Mercedes; Prieto, Pablo; Fortea, Josep // Clinical & Experimental Gastroenterology;2012 Part 2, Vol. 5, p203 

    Background: Several studies have examined the effect of irritable bowel syndrome (IBS) on health outcomes in Western Europe, but less research has focused on the constipation subtype (IBS-C). The current study addresses this gap by comparing patients with IBS-C and matched controls for health...

  • Comparison of the Effectiveness of Cognitive Behavior Therapy and Mindfulness Based Therapy on the Decrease in Symptoms of Patients who suffer from Irritable Bowel Syndrome. Zomorodi, Saeedeh; Rasoulzadeh Tabatabaei, Seyed Kazem; Arbabi, Mohammad; Daryani, Naser Ebrahimi; Fallah, Parviz Azad // Iranian Journal of Gastroenterology & Hepatology (GOVARESH);Summer2013, Vol. 18 Issue 2, p88 

    Background: The current research is performed to compare the effectiveness of two methods of cognitive behavior therapy and mindfulness based therapy in decreasing symptoms of patients who suffer from irritable bowel syndrome. Materials and Methods: This was a quasi-experimental design study...

  • Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. Kaptchuk, Ted J.; Kelley, John M.; Conboy, Lisa A.; Davis, Roger B.; Kerr, Catherine E.; Jacobson, Eric E.; Kirsch, Irving; Schyner, Rosa N.; Bong Hyun Nam; Long T. Nguyen; Min Park; Rivers, Andrea L.; McManus, Claire; Kokkotou, Efi; Drossman, Douglas A.; Goldman, Peter; Lembo, Anthony J. // BMJ: British Medical Journal (International Edition);5/3/2008, Vol. 336 Issue 7651, p999 

    Objective To investigate whether placebo effects can experimentally be separated into the response to three components; assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient-practitioner relationship, and then progressively combined to produce incremental...

  • Management of IBS. Murphy, Kathleen // Australian Journal of Medical Herbalism;2011, Vol. 23 Issue 4, p188 

    The article presents an abstract of the article "Probiotics and Prebiotics in the Management of Irritable Bowel Syndrome - A Review of Recent Clinical Trials and Systematic Reviews" by K. Whelan.

  • Diagnosis, Characterization, and 3-Month Outcome After Detoxification of 39 Patients With Narcotic Bowel Syndrome. Drossman, Douglas A; Morris, Carolyn B; Edwards, Hollie; Wrennall, Christina ED; Weinland, Stephan R; Aderoju, Ademola O; Kulkarni-Kelapure, Renuka R; Hu, Yuming J; Dalton, Christine; Bouma, Megan H; Zimmerman, Joseph; Rooker, Ceciel; Leserman, Jane; Bangdiwala, Shrikant I // American Journal of Gastroenterology;Sep2012, Vol. 107 Issue 9, p1426 

    OBFECTIVES:Narcotic bowel syndrome (NBS) is characterized by a paradoxical increase in abdominal pain associated with continued or escalating dosages of narcotics. This study evaluated the clinical and psychosocial features of patients with NBS and the response to detoxification...

  • Linzess: A Novel Treatment Option for Constipation Associated with Irritable Bowel Syndrome. Goodman, Alice // American Health & Drug Benefits;Apr2013, Vol. 6 Issue 3, p57 

    The article discusses the Food and Drug Administration (FDA) approval for linzess in December 2012 as a new option for the treatment of constipation due to irritable bowel syndrome (IBS). Topics include information about IBS, its symptoms and causes, the FDA-approved linaclotide as a guanylate...

  • Placebo Effect in Clinical Trial Design for Irritable Bowel Syndrome. Shah, Eric; Pimentel, Mark // Journal of Neurogastroenterology & Motility;Apr2014, Vol. 20 Issue 2, p163 

    Ongoing efforts to improve clinical trial design in irritable bowel syndrome have been hindered by high placebo response rates and ineffective outcome measures. We assessed established strategies to minimize placebo effect as well as the various approaches to placebo effect which can affect...

  • Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Atkinson, W.; Sheldon, T. A.; Shaath, N.; Whorwell, P. J. // Gut;Oct2004, Vol. 53 Issue 10, p1459 

    Background: Patients with irritable bowel syndrome (IBS) often feel they have some form of dietary intolerance and frequently try exclusion diets. Tests attempting to predict food sensitivity in IBS have been disappointing but none has utilised IgG antibodies. Aims: To assess the therapeutic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics